The FDA's landmark approval of Revolution Medicines' daraxonrasib (Rasonque) introduces the first multi-selective RAS(ON) tri-complex inhibitor for metastatic pancreatic adenocarcinoma, doubling overall survival over standard chemotherapy.
Newsletter
The week in pipeline, markets, policy, and science — in your inbox.
Fifty-two-week Phase 2 data showed 20% weight loss with monthly dosing, but gastrointestinal dropouts and biological debates over GIP antagonism tempered market euphoria.
Phase 3 data for suzetrigine proved non-opioid pain relief is clinically achievable, but secondary endpoint misses against generic Vicodin highlight the commercial hurdles ahead.
Roche subsidiary Genentech is paying Hanmi Pharmaceutical $190 million upfront for a non-incretin urocortin-2 analog designed to burn fat while sparing lean muscle mass.
Receptor-mediated transcytosis using transferrin receptor-targeting antibody fragments enables systemic intravenous delivery of genetic medicines across the central nervous system.
A 25 August Nature Biomedical Engineering paper shows malignant synapses concentrated at the GBM–brain interface, then tests an intracavitary TrkB-silencing hydrogel that more than doubled median survival in a mouse resection model.
FDA cleared two zanidatamab regimens on 25 August, including a bispecific-plus-PD-1 combination for all HER2+ advanced GEA regardless of PD-L1 status, on Phase 3 data already in NEJM.